NGM Biopharmaceuticals (NGM) PT Raised to $36 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Raymond James Upgrades NGM Biopharmaceuticals (NGM) to Strong Buy; 'Complement Validated in GA'
September 12, 2021 9:58 PM EDTRaymond James analyst Steven Seedhouse upgraded NGM Biopharmaceuticals (NASDAQ: NGM) from Outperform to Strong Buy with a price target of $39.00.
The analyst commented, "Phase 3 data for Apellis pegcetacoplan in GA provide strong evidence that complement inhibition is an active mechanism in... More
